Russian pharma is calling the Varangians

Localization of pharmaceutical production – the way to innovative medicine

ARFP Press ServiceOn June 26-27, a visiting meeting of the Formulary Committee "Healthcare Reform: economic validity or social responsibility" was held in Yaroslavl?

The event brought together representatives of federal executive authorities, industry associations and associations, regional healthcare professionals.

Localization of production in Russia became an actual topic of discussion. The high level of unmet medical needs of Russians, the dynamic development of the economy and government initiatives aimed at modernizing healthcare determine the attractiveness of Russia for the international pharmaceutical business.

This cooperation is mutually beneficial: the Russian economy receives world–class technologies and equipment, new jobs and production management methods, and partners - a guaranteed sales market. Nevertheless, there are enough problems when transferring production facilities according to Western standards to domestic soil.

To address these issues, the Government proposed the creation of specialized clusters in the country. One of the examples of a successful project is the Yaroslavl cluster of modern Pharmaceutical Industry and innovative Medicine, on the territory of which such pharmaceutical companies as Takeda, R-Pharm are located, the Teva plant is being built.

"Localization of production sites in the Russian Federation by foreign companies is the most important component of Pharma 2020. The Yaroslavl cluster of the modern pharmaceutical industry and innovative medicine is a vivid example of a correctly chosen vector. But building a factory is half the battle. It is important to take into account modern healthcare needs in new technologies and drugs. Such meetings of scientists, practitioners and manufacturers, business representatives allow us to identify the main and sought-after areas of the industry to achieve real positive changes in health indicators. I am sure that those drugs that are already being produced by local pharmaceutical manufacturers and will enter the market in the near future will significantly affect the capabilities of Russian healthcare for the prevention and treatment of diseases that seriously affect mortality and life expectancy," said Viktor Dmitriev, Director General of ARFP, speaking at the meeting.

Portal "Eternal youth" http://vechnayamolodost.ru30.06.2014